Abstracts Archive - Page 1603 of 2616 - ACR Meeting Abstracts

Abstract Number: 101 • 2017 Pediatric Rheumatology Symposium
Defining Active Features of Juvenile Localized Scleroderma
Suzanne Li¹, Xiaohu Li², Elena Pope³, Katie G. Stewart⁴, Gloria Higgins⁵, C. Egla Rabinovich⁶, Kathleen O'Neil⁷, Kathleen Haines⁸, Ronald Laxer⁹, Marilynn Punaro¹⁰, Heidi Jacobe¹¹, Knut Wittkowski¹², Themba Nyirenda¹³, Ivan Foeldvari¹⁴ and Kathryn S. Torok¹⁵, ¹Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ²Mathematical Sciences, Stevens Institute of Technology, Hoboken, NJ, ³Dermatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ⁵Pediatrics, Nationwide Children's Hospital, Columbus, OH, ⁶Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ⁷Pediatrics, Indiana University, Indianapolis, IN, ⁸Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ⁹Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Texas Scottish Rite Hospital for Children, Dallas, TX, ¹¹Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ¹²Rockefeller University, New York, NY, ¹³Hackensack University Medical Center, Hackensack, NJ, ¹⁴Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, ¹⁵Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA
Background/Purpose: Juvenile localized scleroderma (jLS) is the most common form of childhood scleroderma. Because of its chronicity and association with extracutaneous involvement, children are at…
Abstract Number: 120 • 2017 Pediatric Rheumatology Symposium
Use Of Thalidomide From A Tertiary Level Pediatric Rheumatology Centre In India
Manjari Agarwal¹, Abhay Shivpuri² and Sujata Sawhney³, ¹Institute of Child Health, Attending Consultant, New Delhi, India, ²Division of Pediatric Rheumatology,Institute of Child Health, Post Doctoral Fellow, New Delhi, India, ³Paediatric rheumatology, Senior Consultant, New Delhi, India
Background/Purpose: Thalidomide is an effective agent for several pediatric rheumatic diseases: Systemic onset Juvenile idiopathic arthritis(SOJIA), Behcet's disease and recalcitrant skin disease in cSLE to…
Abstract Number: 147 • 2017 Pediatric Rheumatology Symposium
Epigenetic and Transcriptomic Profiling of Primary Juvenile Idiopathic Arthritis Patient Cells: Better Understanding of Disease Pathogenesis
Lucas Picavet¹, Janneke Peeters², Sandra Coenen³, Arjan Boltjes⁴, Femke van Wijk⁵, Paul Coffer², Bas Vastert⁶ and Jorg van Loosdregt⁷, ¹Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, Netherlands, ²Center for Molecular Medicine and Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, Netherlands, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Laboratory for Translational Immunity, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Division of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: For many autoimmune diseases, including Juvenile Idiopathic Arthritis (JIA), the molecular mechanisms remain elusive. JIA can be used as a model to study autoimmune…
Abstract Number: 125 • 2017 Pediatric Rheumatology Symposium
How Do Health Literacy, Numeric Competencies and Patient Activation Impact Transition Readiness in Adolescents and Young Adults with Rheumatologic Diseases?
Samuel Lazaroff¹, Mary-Kate Tompkins², Alexa Meara³, Ellen Peters⁴ and Stacy P. Ardoin⁵, ¹College of Medicine, Ohio State University, Columbus, OH, ²The Ohio State University, Columbus, OH, ³Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ⁴Ohio State University, Columbus, OH, ⁵Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: Transition from pediatric to adult health care is a vulnerable time during which gaps in care may negatively affect disease outcomes. Validated measures including…
Abstract Number: 39 • 2017 Pediatric Rheumatology Symposium
Rheumapalooza: A rheumatology curriculum in evolution
Kristen Hayward¹ and Helen M. Emery², ¹Pediatric Rheumatology, University of Washington & Seattle Children's Hospital, Seattle, WA, ²rheumatology, Seattle Childrens Hospital, Seattle, WA
Background/Purpose: Rheumapalooza was implemented in 2008 as an elective course with support from an ACR/REF Clinical Scholar Educator Award.1 The course was incorporated into the…
Abstract Number: 143 • 2017 Pediatric Rheumatology Symposium
Influence of Age and Sex on Collagen-Induced Arthritis
Tracy Wilson-Gerwing¹, Arash Panahifar², David M.L. Cooper² and Alan Rosenberg¹, ¹Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²Anatomy and Cell Biology, University of Saskatchewan, Saskatoon, SK, Canada
Background/Purpose: Age and sex differences are found in certain subsets of juvenile idiopathic arthritis (JIA). Collagen Induced Arthritis (CIA) in rodents has utility in assessing…
Abstract Number: 1 • 2017 Pediatric Rheumatology Symposium
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis
C. April Bingham¹, Jesse Pratt², Cagri Yildirim-Toruner³, Ronald Laxer⁴, Beth Gottlieb⁵, Jennifer Weiss⁶, Tzielan Lee⁷, Sheetal S. Vora⁸, Jon Burnham⁹, Julia Harris¹⁰, Judyann C. Olson¹¹, Murray Passo¹², Michelle Batthish¹³, Michael Shishov¹⁴, Kerry Ferraro¹⁵, Deborah M. Levy¹⁶, Christine O'Brien¹⁷, Kristi Whitney-Mahoney¹⁷, Nancy Griffin¹⁸, Anne Paul¹⁹ and Esi Morgan²⁰, ¹Penn State Health Children's Hospital, Hershey, PA, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁴Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁶Hackensack University Medical Center, Hackensack, NJ, ⁷Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁸Pediatric Rheumatology, Levine Children's Hospital, Charlotte, NC, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰Children's Mercy Kansas City, Kansas City, MO, ¹¹Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹²Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC, ¹³Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁴Pediatric Rheumatology, Phoenix Children's Hospital, Phoenix, AZ, ¹⁵Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ¹⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁷The Hospital for Sick Children, Toronto, ON, Canada, ¹⁸James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁹Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a growing multi-center network organized on a learning health system model designed to improve outcomes…
Abstract Number: 113 • 2017 Pediatric Rheumatology Symposium
Exploring the role of pediatric rheumatologists in the diagnosis and management of autoimmune encephalitis
Eyal Muscal¹, Heather Van Mater², Tania Cellucci³, Dominic Co⁴, Jennifer Frankovich⁵, Marisa S. Klein-Gitelman⁶, Marinka Twilt⁷ and Susanne Benseler⁸, ¹Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Pediatrics/ Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ³McMaster University, hamilton, ON, Canada, ⁴Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁵Pediatrics, Standford University, Palo Alto, CA, ⁶Div of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/NW University, Chicago, IL, ⁷Paediatrics, University Of Calgary, Calgary, AB, Canada, ⁸Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: Autoimmune encephalitis (AE) encompasses a spectrum of immune-mediated brain disorders that cause severe neuropsychiatric manifestations. These disorders often lead to protracted hospital stays, complex…
Abstract Number: 146 • 2017 Pediatric Rheumatology Symposium
Age-Related Differences in Neuronal High Mobility Group Box-1 and Resolvin D1 Receptors in Collagen-Induced Arthritis
Tracy Wilson-Gerwing and Alan Rosenberg, Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada
Background/Purpose: More thorough understanding of age-related molecular interactions that drive inflammation and inflammatory pain is required to help guide evidenced-based, age appropriate treatment strategies that…
Abstract Number: 67 • 2017 Pediatric Rheumatology Symposium
Relapse and Remission in Children with Chronic Non-Infectious Uveitis Treated with Methotrexate and Tumor Necrosis Factor-α Inhibitors
Courtney McCracken¹, Curtis Travers¹, Kirsten Jenkins², Carolyn Drews-Botsch³, Steven Yeh⁴, Sampath Prahalad^1,5 and Sheila Angeles-Han^6,7, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁴Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁵Pediatrics, Emory Children's Center, Atlanta, GA, ⁶Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Pediatrics, University of Cincinnati, Cincinnati, OH
Background/Purpose: Methotrexate (MTX) and tumor necrosis factor-α inhibitors (TNFi) are common treatments for children with chronic non-infectious uveitis (NIU). Optimal duration of treatment prior to…
Abstract Number: 92 • 2017 Pediatric Rheumatology Symposium
Mycophenolate Mofetil is an Effective Induction Therapy Agent in Childhood-onset Pure Membranous Lupus Nephritis
Maria Pereira¹, Eyal Muscal², Marietta DeGuzman³, Anna Carmela Sagcal-Gironella⁴ and Scott E. Wenderfer⁵, ¹Immunology, Allergy & Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁵Pediatrics-Renal, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Treatment guidelines for childhood-onset class V membranous lupus nephritis (MLN) have not yet been established. The addition of mycophenolate mofetil (MMF) has shown improvement…
Abstract Number: 153 • 2017 Pediatric Rheumatology Symposium
Training pediatric rheumatology fellows intra-articular injection techniques and skills using a cadaver based musculoskeletal curriculum
Baruch Goldberg¹, Amanda Brown² and Monica Marcus³, ¹Pediatric Rheumatology, Texas Children's Hospital, Houston, TX, ²Allergy, Immunology and Rheumatology, Texas Children's Hospital, houston, TX, ³Pediatric Immunology, Allergy and Rheumatology, Texas Children's Hospital, Houston, TX
Background/Purpose: Intra-articular injections are important to treat children with arthritis. Practice differences, comfort levels, and reimbursement can decrease fellow exposure to this skill. The purpose…
Abstract Number: 50 • 2017 Pediatric Rheumatology Symposium
Tumor necrosis factor-α (TNFα) inhibitor-induced psoriasis in juvenile idiopathic arthritis (JIA) patients
Daniel Groth¹, Sivia Lapidus², Simona Nativ² and Maria Perez³, ¹Goryeb Children's Hospital, Morristown, NJ, ²Pediatric Rheumatology, Goryeb Children's Hospital, Morristown, NJ, ³Pediatric Gastroenterology, Goryeb Children's Hospital, Morristown, NJ
Background/Purpose: Occurrence of psoriasis while on TNFα antagonists is a paradoxical effect of agents that treat psoriasis, and is described in larger cohorts of inflammatory…
Abstract Number: 68 • 2017 Pediatric Rheumatology Symposium
HLA-DRB1 in Non-Hispanic African American Children with Juvenile Idiopathic Arthritis and Chronic Anterior Uveitis
Lai Hin Kimi Chan¹, Courtney McCracken¹, Kirsten Jenkins², Steven Yeh³, Purnima Patel⁴, Sampath Prahalad¹ and Sheila Angeles-Han⁵, ¹Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Ophthalmology, Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine, Atlanta, GA, ⁵Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: HLA-DRB1*08, 11 and 13 are strong risk alleles for various juvenile idiopathic arthritis (JIA) subtypes. We reported that carriage of DRB1*11 and *13 increased…
Abstract Number: 104 • 2017 Pediatric Rheumatology Symposium
Rituximab Treatment for Chronic Steroid-Dependent Henoch-Schonlein Purpura
Esraa M. A. Eloseily^1,2, Courtney Crayne¹, Melissa L Mannion³, Saji P Azerf⁴, Peter Weiser¹, Timothy Beukelman¹, Matthew L. Stoll¹, Dan Feig⁵, Prescott Atkinson⁶ and Randy Q. Cron¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Pediatrics, Assiut University, Assiut, Egypt, ³Pediatric rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴School of medicine, Univesity of Alabama at Birmingham,, Birmingham, AL, ⁵Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Allergy and Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Henoch-Schonlein purpura (HSP) is a small vessel vasculitis characterized by non-thrombocytopenic purpura, abdominal pain, arthritis, and glomerulonephritis. Typically, HSP is self-limited, but more severe…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].